Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (61)

« Back to Publications

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group ., (2026), Lancet Infect Dis, 26, 34 - 45

The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study.

Peto L. et al, (2025)

The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study

Peto L. et al, (2025), eLife, 13

Platform Trials to Assess Therapeutics in Patients Hospitalized With Influenza.

Waite AAC. et al, (2025), J Infect Dis, 232, S254 - S261

Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group ., (2025), Lancet Infect Dis, 25, 1000 - 1010

The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study

Peto L. et al, (2025)

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group ., (2025), EClinicalMedicine, 81

Long-term follow-up of treatment comparisons in RECOVERY: a randomised, open-label, platform trial for patients hospitalised with COVID-19

Horby P. et al, (2025)

Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)

Horby P. et al, (2025)

In Practice: RECOVERY Trial

HORBY P. et al, (2024)

Community Involvement in an Outbreak-One Year on for Mpox.

Cheyne A. et al, (2024), Clin Infect Dis, 79, 278 - 280

The impact of different antimicrobial exposures on the gut microbiome in the ARMORD observational study

Peto L. et al, (2024)

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England.

Pessoa-Amorim G. et al, (2024), Trials, 25

High-dose corticosteroid therapy in COVID-19: the RECOVERY trial - Authors' reply.

Peto L. et al, (2024), Lancet, 403, 1339 - 1340

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

RECOVERY Collaborative Group ., (2024), Lancet Child Adolesc Health, 8, 190 - 200

Load More

1
2
3
4
5